Ergonovine provocation to assess efficacy of long-term therapy with calcium antagonists in Prinzmetal's variant angina

Michael D. Winniford, Stacey M. Johnson, David R. Mauritson, L. David Hillis

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Original languageEnglish
Pages (from-to)684-688
Number of pages5
JournalThe American Journal of Cardiology
Volume51
Issue number5
DOIs
StatePublished - Mar 1 1983
Externally publishedYes

Fingerprint

Ergonovine
Calcium
Chest Pain
Ambulatory Electrocardiography
Therapeutics
Nifedipine
Verapamil
Placebos
Prinzmetal's variant angina

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Ergonovine provocation to assess efficacy of long-term therapy with calcium antagonists in Prinzmetal's variant angina. / Winniford, Michael D.; Johnson, Stacey M.; Mauritson, David R.; Hillis, L. David.

In: The American Journal of Cardiology, Vol. 51, No. 5, 01.03.1983, p. 684-688.

Research output: Contribution to journalArticle

Winniford, Michael D. ; Johnson, Stacey M. ; Mauritson, David R. ; Hillis, L. David. / Ergonovine provocation to assess efficacy of long-term therapy with calcium antagonists in Prinzmetal's variant angina. In: The American Journal of Cardiology. 1983 ; Vol. 51, No. 5. pp. 684-688.
@article{7ffe8b28832f45b58ca6f4b479f8824e,
title = "Ergonovine provocation to assess efficacy of long-term therapy with calcium antagonists in Prinzmetal's variant angina",
abstract = "In the patient with Prinzmetal's variant angina, the response to therapy with calcium antagonists may be assessed symptomatically, electrocardiographically (that is, by ambulatory electrocardiographic monitoring), or by response to ergonovine provocation. Although some studies have suggested a good relation between anginal frequency and ergonovine responsiveness in these patients, none has compared ambulatory electrocardiographic activity with the results of ergonovine provocation during the long-term administration of calcium antagonists. Therefore, the present study was performed to compare ergonovine responsiveness with both clinical and ambulatory electrocardiographic activity in patients with Prinzmetal's variant angina during long-term therapy with placebo, verapamil, and nifedipine. Accordingly, 27 patients with variant angina (19 men and 8 women, mean age 52 years) received placebo and verapamil for 2 months each, after which 23 of the 27 also received nifedipine for 2 months. All patients kept a diary of chest pains, and all had weekly 24-hour 2-channel ambulatory electrocardiographic (Holter) monitoring, from which episodes of transient S-T segment deviation were quantitated. During the final week of therapy with each agent, ergonovine was administered, beginning at 0.025 mg and incrementally increasing to 0.20 mg. It was discontinued when the patient had chest pain with S-T segment elevation ≥0.1 mV or received a total dose of 0.50 mg. Of the 74 tests, 59 were negative; 6 of the negative tests occurred during a treatment period in which the patient had >10 chest pains/week and >25 episodes of S-T segment deviation/week. Of the 15 positive tests, 8 became positive during administration of <0.20 mg ergonovine; 5 of the positive tests occurred during a treatment period in which the patient had no chest pain or S-T segment deviation. Thus, in patients with variant angina, disease activity cannot be monitored reliably by ergonovine provocation because some patients have negative ergonovine tests at a time of marked clinical and electrocardiographic activity, whereas others have positive tests at a time of little (or no) disease activity.",
author = "Winniford, {Michael D.} and Johnson, {Stacey M.} and Mauritson, {David R.} and Hillis, {L. David}",
year = "1983",
month = "3",
day = "1",
doi = "10.1016/S0002-9149(83)80115-5",
language = "English",
volume = "51",
pages = "684--688",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Ergonovine provocation to assess efficacy of long-term therapy with calcium antagonists in Prinzmetal's variant angina

AU - Winniford, Michael D.

AU - Johnson, Stacey M.

AU - Mauritson, David R.

AU - Hillis, L. David

PY - 1983/3/1

Y1 - 1983/3/1

N2 - In the patient with Prinzmetal's variant angina, the response to therapy with calcium antagonists may be assessed symptomatically, electrocardiographically (that is, by ambulatory electrocardiographic monitoring), or by response to ergonovine provocation. Although some studies have suggested a good relation between anginal frequency and ergonovine responsiveness in these patients, none has compared ambulatory electrocardiographic activity with the results of ergonovine provocation during the long-term administration of calcium antagonists. Therefore, the present study was performed to compare ergonovine responsiveness with both clinical and ambulatory electrocardiographic activity in patients with Prinzmetal's variant angina during long-term therapy with placebo, verapamil, and nifedipine. Accordingly, 27 patients with variant angina (19 men and 8 women, mean age 52 years) received placebo and verapamil for 2 months each, after which 23 of the 27 also received nifedipine for 2 months. All patients kept a diary of chest pains, and all had weekly 24-hour 2-channel ambulatory electrocardiographic (Holter) monitoring, from which episodes of transient S-T segment deviation were quantitated. During the final week of therapy with each agent, ergonovine was administered, beginning at 0.025 mg and incrementally increasing to 0.20 mg. It was discontinued when the patient had chest pain with S-T segment elevation ≥0.1 mV or received a total dose of 0.50 mg. Of the 74 tests, 59 were negative; 6 of the negative tests occurred during a treatment period in which the patient had >10 chest pains/week and >25 episodes of S-T segment deviation/week. Of the 15 positive tests, 8 became positive during administration of <0.20 mg ergonovine; 5 of the positive tests occurred during a treatment period in which the patient had no chest pain or S-T segment deviation. Thus, in patients with variant angina, disease activity cannot be monitored reliably by ergonovine provocation because some patients have negative ergonovine tests at a time of marked clinical and electrocardiographic activity, whereas others have positive tests at a time of little (or no) disease activity.

AB - In the patient with Prinzmetal's variant angina, the response to therapy with calcium antagonists may be assessed symptomatically, electrocardiographically (that is, by ambulatory electrocardiographic monitoring), or by response to ergonovine provocation. Although some studies have suggested a good relation between anginal frequency and ergonovine responsiveness in these patients, none has compared ambulatory electrocardiographic activity with the results of ergonovine provocation during the long-term administration of calcium antagonists. Therefore, the present study was performed to compare ergonovine responsiveness with both clinical and ambulatory electrocardiographic activity in patients with Prinzmetal's variant angina during long-term therapy with placebo, verapamil, and nifedipine. Accordingly, 27 patients with variant angina (19 men and 8 women, mean age 52 years) received placebo and verapamil for 2 months each, after which 23 of the 27 also received nifedipine for 2 months. All patients kept a diary of chest pains, and all had weekly 24-hour 2-channel ambulatory electrocardiographic (Holter) monitoring, from which episodes of transient S-T segment deviation were quantitated. During the final week of therapy with each agent, ergonovine was administered, beginning at 0.025 mg and incrementally increasing to 0.20 mg. It was discontinued when the patient had chest pain with S-T segment elevation ≥0.1 mV or received a total dose of 0.50 mg. Of the 74 tests, 59 were negative; 6 of the negative tests occurred during a treatment period in which the patient had >10 chest pains/week and >25 episodes of S-T segment deviation/week. Of the 15 positive tests, 8 became positive during administration of <0.20 mg ergonovine; 5 of the positive tests occurred during a treatment period in which the patient had no chest pain or S-T segment deviation. Thus, in patients with variant angina, disease activity cannot be monitored reliably by ergonovine provocation because some patients have negative ergonovine tests at a time of marked clinical and electrocardiographic activity, whereas others have positive tests at a time of little (or no) disease activity.

UR - http://www.scopus.com/inward/record.url?scp=0020657031&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020657031&partnerID=8YFLogxK

U2 - 10.1016/S0002-9149(83)80115-5

DO - 10.1016/S0002-9149(83)80115-5

M3 - Article

C2 - 6338688

AN - SCOPUS:0020657031

VL - 51

SP - 684

EP - 688

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 5

ER -